It's now the second treatment approved by the FDA to prevent RSV in infants and the first vaccine.
It uses maternal immunization, which refers to vaccinating pregnant mothers so they can pass protective antibodies to their fetuses.
"When you think globally, this vaccine could potentially have a huge public health impact," Gurtman told CNBC.
The FDA in mid-July approved an RSV monoclonal antibody from Sanofi and AstraZeneca that is directly administered to infants.
The shot would help the U.S. combat the upcoming RSV season as it comes off an unusually severe year.
Persons:
It's, Alejandra Gurtman, Gurtman, Dr, Peter Marks
Organizations:
Drug Administration, Pfizer, FDA, Centers for Disease Control, Prevention, CNBC, Sanofi, AstraZeneca, CDC
Locations:
U.S